Introduction- Primitive tracheal tumors represent a rare entity whose management, when unresectable, remains challenging. Primary aim of this study was to explore the survival and the factors influencing prognosis of patients with unresectable primitive tracheal tumor undergoing multimodal treatment integrating interventional bronchoscopy and radiotherapy. Materials and methods- This retrospective cohort study was conducted at the University Hospital of Modena (Italy) over a 10-year period (January 2010-January 2020) analyzing patients with unresectable primary tracheal tumor receiving interventional bronchoscopy treatment followed by radiotherapy. Survival analysis was conducted for the whole population and according to histology, development of metastasis, stent placement and the onset of disease relapse. The raw and independent association between potential risk factor and 5-year mortality and the reported complications were investigated. Results- A total of 12 patients were included. Five-year survival rate was 42% with a median survival time of 26.7 (4.1 – 82) months. Survivors showed a higher prevalence of cystic-adenoid histology (80% VS 14%, p=0.07), while patients who were dead at 5 years were those with a more advanced T (prevalence of T2 71% VS 0%, p=0.03) and a lower response to first line treatment (57% VS 0%). Treatment complications accounted for stent dislocation (33%) and the onset of granuloma (18%), while no major side effects were reported. The presence of cystic-adenoid histology resulted in significantly improved 5-year survival rate (80% versus 14%, p=0.01). The onset of distal metastasis, the occurrence of disease relapse and the placement of tracheal stent did not result significantly associated with lower survival. Among analysed variables, only the presence of cystic-adenoid histology resulted independently associated with survival (OR=0.1, p=0.04). Conclusions- Multimodal treatment including interventional bronchoscopy and associated radiotherapy for unresectable primary tracheal tumors seems not burdened by significant complications and may provide benefits in terms of survival for those patients with cystic-adenoid histology.

Integrated endoscopic treatment of primitive unresectable tracheal tumor: the INTACT retrospective cohort study / Marchioni, Alessandro; Manicardi, Linda; Tonelli, Roberto; Tabbì, Luca; Andrisani, Dario; Lamesta, Antonio; Mocellin, Anna; Bruzzi, Giulia; Cappiello, Gaia; Andreani, Alessandro; Mattioli, Francesco; Filosso, Pierluigi; Clini, Enrico. - In: JOURNAL OF THORACIC DISEASE. - ISSN 2072-1439. - 16:5(2024), pp. 2811-2821. [10.21037/jtd-23-738]

Integrated endoscopic treatment of primitive unresectable tracheal tumor: the INTACT retrospective cohort study.

Roberto Tonelli;Antonio Lamesta;Anna Mocellin;Giulia Bruzzi;Francesco Mattioli;Pierluigi Filosso;Enrico Clini
2024

Abstract

Introduction- Primitive tracheal tumors represent a rare entity whose management, when unresectable, remains challenging. Primary aim of this study was to explore the survival and the factors influencing prognosis of patients with unresectable primitive tracheal tumor undergoing multimodal treatment integrating interventional bronchoscopy and radiotherapy. Materials and methods- This retrospective cohort study was conducted at the University Hospital of Modena (Italy) over a 10-year period (January 2010-January 2020) analyzing patients with unresectable primary tracheal tumor receiving interventional bronchoscopy treatment followed by radiotherapy. Survival analysis was conducted for the whole population and according to histology, development of metastasis, stent placement and the onset of disease relapse. The raw and independent association between potential risk factor and 5-year mortality and the reported complications were investigated. Results- A total of 12 patients were included. Five-year survival rate was 42% with a median survival time of 26.7 (4.1 – 82) months. Survivors showed a higher prevalence of cystic-adenoid histology (80% VS 14%, p=0.07), while patients who were dead at 5 years were those with a more advanced T (prevalence of T2 71% VS 0%, p=0.03) and a lower response to first line treatment (57% VS 0%). Treatment complications accounted for stent dislocation (33%) and the onset of granuloma (18%), while no major side effects were reported. The presence of cystic-adenoid histology resulted in significantly improved 5-year survival rate (80% versus 14%, p=0.01). The onset of distal metastasis, the occurrence of disease relapse and the placement of tracheal stent did not result significantly associated with lower survival. Among analysed variables, only the presence of cystic-adenoid histology resulted independently associated with survival (OR=0.1, p=0.04). Conclusions- Multimodal treatment including interventional bronchoscopy and associated radiotherapy for unresectable primary tracheal tumors seems not burdened by significant complications and may provide benefits in terms of survival for those patients with cystic-adenoid histology.
2024
16-mag-2024
16
5
2811
2821
Integrated endoscopic treatment of primitive unresectable tracheal tumor: the INTACT retrospective cohort study / Marchioni, Alessandro; Manicardi, Linda; Tonelli, Roberto; Tabbì, Luca; Andrisani, Dario; Lamesta, Antonio; Mocellin, Anna; Bruzzi, Giulia; Cappiello, Gaia; Andreani, Alessandro; Mattioli, Francesco; Filosso, Pierluigi; Clini, Enrico. - In: JOURNAL OF THORACIC DISEASE. - ISSN 2072-1439. - 16:5(2024), pp. 2811-2821. [10.21037/jtd-23-738]
Marchioni, Alessandro; Manicardi, Linda; Tonelli, Roberto; Tabbì, Luca; Andrisani, Dario; Lamesta, Antonio; Mocellin, Anna; Bruzzi, Giulia; Cappiello,...espandi
File in questo prodotto:
File Dimensione Formato  
Marchioni (Endoscopic treatment of unresectable tracheal tumor-2024).pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 685.11 kB
Formato Adobe PDF
685.11 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1338726
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact